Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank McCormick

Showing results (271-280 of 303) with videos related to

Pageof 31
Sort By:
Plos One|February 8, 2014
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, et al.
Cancer Discovery|December 16, 2014
Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction mapMaria M Martins, Alicia Y Zhou, Alexandra Corella, et al.
Nature Medicine|November 28, 2018
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancerKhyati N Shah, Roma Bhatt, Julia Rotow, et al.
Cell Reports Methods|October 21, 2021
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signalingJeffrey R Whiteaker, Kanika Sharma, Melissa A Hoffman, et al.
American Journal of Medical Genetics. Part A|April 17, 2008
Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007Katherine A Rauen, Erin Hefner, Kristin Carrillo, et al.
American Journal of Medical Genetics. Part A|January 9, 2020
Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathiesAndrea M Gross, Megan Frone, Karen W Gripp, et al.
Nature Communications|January 12, 2024
Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistanceHarish N Vasudevan, Emily Payne, Cyrille L Delley, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS <sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibitionKatherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.
Molecular Cell|May 25, 2022
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1Wenjing Su, Radha Mukherjee, Rona Yaeger, et al.
Cancer Research|January 17, 2009
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibitionOlga K Mirzoeva, Debopriya Das, Laura M Heiser, et al.
Pageof 31

Showing results (271-280 of 303) with videos related to

Sort By:
Pageof 31
Plos One|February 8, 2014
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, et al.
Cancer Discovery|December 16, 2014
Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction mapMaria M Martins, Alicia Y Zhou, Alexandra Corella, et al.
Nature Medicine|November 28, 2018
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancerKhyati N Shah, Roma Bhatt, Julia Rotow, et al.
Cell Reports Methods|October 21, 2021
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signalingJeffrey R Whiteaker, Kanika Sharma, Melissa A Hoffman, et al.
American Journal of Medical Genetics. Part A|April 17, 2008
Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007Katherine A Rauen, Erin Hefner, Kristin Carrillo, et al.
American Journal of Medical Genetics. Part A|January 9, 2020
Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathiesAndrea M Gross, Megan Frone, Karen W Gripp, et al.
Nature Communications|January 12, 2024
Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistanceHarish N Vasudevan, Emily Payne, Cyrille L Delley, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS <sup>G12C</sup> suppresses PI3Kα and leads to potent tumor inhibitionKatherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.
Molecular Cell|May 25, 2022
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1Wenjing Su, Radha Mukherjee, Rona Yaeger, et al.
Cancer Research|January 17, 2009
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibitionOlga K Mirzoeva, Debopriya Das, Laura M Heiser, et al.
Pageof 31